Renal biomarkers in Juvenile-onset systemic lupus erythematosus

Watson, Louise
Renal biomarkers in Juvenile-onset systemic lupus erythematosus. Doctor of Philosophy thesis, University of Liverpool.

[thumbnail of WatsonLou_Nov2012_10293.pdf] PDF
WatsonLou_Nov2012_10293.pdf - Author Accepted Manuscript
Access to this file is embargoed until Unspecified.
After the embargo period this will be available under License Creative Commons Attribution No Derivatives.

Download (39MB)
[thumbnail of WatsonLou_Nov2012_10293_abridged.pdf] PDF
WatsonLou_Nov2012_10293_abridged.pdf - Unspecified
Available under License Creative Commons Attribution No Derivatives.

Download (6MB)


Background: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a rare, but severe, autoimmune condition with lupus nephritis (LN) occurring in up to 80% of patients and predisposing to an increased mortality. Aims/Objectives: As part of the UK JSLE Cohort Study this study aimed to identify whether standard and/or novel biomarkers are useful for monitoring LN and to assess whether novel urine biomarkers are released from the podocyte (kidney epithelial cell). Method/Results: A prospective translational study encompassing a clinical cross sectional biomarker analysis, a longitudinal observational biomarker study and scientific laboratory investigation. The study had full ethical approval. Cross sectional investigation identified whether (a) urine biomarkers (monocyte chemoattractant protein-1, MCP1; alpha-1-acid glycoprotein, AGP; interferon producing protein-10, IP10; neutrophil gelatinase associated lipocalin, NGAL) or (b) plasma biomarkers (interferon-gamma, IFN-γ; IP10; tumour necrosis factor alpha, TNF-α; interleukin 6, IL6; IL1β; MCP1; IL13; vascular endothelial growth factor, VEGF) are increased in JSLE patients with active renal disease. JSLE patients (n=60) and healthy controls (n=23) were recruited. Of JSLE patients, 45 were female (75%) and aged 14.7 (12.2-16.1) years. All had ≥ 4 ACR SLE classification criteria (median 5, range 4-9). Urinary MCP1 concentration increased in patients with JSLE active renal disease compared to JSLE non-active renal disease (582 (251-2100) pg/mgCr; 207 (121-280) pg/mgCr; p=0.018) and healthy controls (117 (68-193) pg/mgCr; p=0.005), AGP concentration also increased (JSLE active renal disease: 1517 (753-2389) ng/mgCr; JSLE non-active renal disease: 485 (212-967) ng/mgCr; p=0.027; healthy controls 313 (108-729) ng/mgCr; p=0.013). On cross sectional testing IP10 and NGAL showed no significant difference. Plasma analysis demonstrated increased IL-13 and a trend toward increased IFN-γ, TNF-α, IL-6 and VEGF in patients with JSLE active renal disease (n=12). For prospective longitudinal analysis, JSLE samples were collected at clinical reviews and standard/novel biomarkers assessed against disease activity. The longitudinal JSLE cohort (n=64), seen at 3 (IQR: 2-5) clinical reviews over 364 (182-532) days were aged 14.1 (11.8-15.8) years and 80% female. Active renal episodes had increased concentration of; MCP-1, NGAL, ESR, anti-double stranded DNA, urine albumin:creatinine ratio (UACR), creatinine, and reduced complement 3 (C3), C4 and lymphocytes. On multivariate analysis, MCP-1 and C3 were independent variables (p

Item Type: Thesis (Doctor of Philosophy)
Additional Information: Date: 2012-11 (completed)
Divisions: Faculty of Health and Life Sciences
Depositing User: Symplectic Admin
Date Deposited: 04 Sep 2013 11:38
Last Modified: 16 Dec 2022 04:38
DOI: 10.17638/00010293